Imatinib is a Type-2 kinase inhibitor. Its main inhibitory activity is against ABL kinase, but it has significant action at secondary targets including platelet-derived growth factor receptor (PDGFR) and stem cell growth factor receptor (KIT).Coronavirus
: imatinib is reported to block Spike protein-induced SARS-CoV and MERS-CoV fusion in vitro
], potentially by blocking Abl2 at the endosomal membrane and disrupting the actin dynamics that are required for virus-host fusion [2
]. It will be informative to determine if this holds true for SARS-CoV-2, and whether re-purposing of imatinib and/or newer Abl kinase inhibitors (dasatinib
) could be a viable strategy against COVID-19. This approach would likely to be most effective during the early stage of infection.
View more information in the IUPHAR Pharmacology Education Project: imatinib